Effectiveness and Safety of Risankizumab in Psoriasis
abstract
This abstract is available on the publisher's site.
Access this abstract nowRisankizumab is a humanized IgG monoclonal antibody that binds with high affinity and specificity to the p19 subunit and selectively inhibits IL-23, critical for psoriatic inflammation. In phase-3 trials (UltIMMa-1, UltIMMa-2 and IMMvent) risankizumab demonstrated early and sustained efficacy at 12-week dosing in patients with moderate-to-severe psoriasis.1,2 To date, limited real-life data are available on its effectiveness and safety.3
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
A Multicenter Study on Effectiveness and Safety of Risankizumab in Psoriasis: An Italian 16-Week Real-Life Experience During the COVID-19 Pandemic
J Eur Acad Dermatol Venereol 2020 Oct 20;[EPub Ahead of Print], K Hansel, A Zangrilli, L Bianchi, K Peris, A Chiricozzi, A Offidani, F Diotallevi, MC Fargnoli, M Esposito, P Amerio, G Gualdi, L Bianchi, L StingeniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This evaluation of risankizumab in Italy at the beginning of the COVID-19 pandemic shows us that this medication is effective (nearly 50% PASI-100) and safe. A couple interesting notes: Patients with a BMI <25 did better than those with a BMI >25, patients who were worse at baseline had greater percentage improvements, and patients with a history of biologic use in the past achieved a similar PASI-75 as biologic-naïve patients. Although we can expect risankizumab to be highly effective in all patients, especially the more severe cases, we should continue to emphasize weight reduction in obese patients to increase our chances of even better therapeutic success.